Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening
Benign prostatic hyperplasia (BPH) is a common disease affecting male urinary system function and quality of life, with its incidence increasing due to population ageing and unhealthy lifestyles. Modern medicine mainly adopts symptomatic treatments such as 5-alpha reductase inhibitors and alpha1 adr...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1584766/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850207723802591232 |
|---|---|
| author | Xiangpeng Kong Xiangpeng Kong Haiqin Ren Ke Pei Yajun Yao Zhigang Liang Yunfeng Xue Shuang Liang Tongtong Li Jing Zhang Yuxia Guo Miaorong Pei Huifeng Li |
| author_facet | Xiangpeng Kong Xiangpeng Kong Haiqin Ren Ke Pei Yajun Yao Zhigang Liang Yunfeng Xue Shuang Liang Tongtong Li Jing Zhang Yuxia Guo Miaorong Pei Huifeng Li |
| author_sort | Xiangpeng Kong |
| collection | DOAJ |
| description | Benign prostatic hyperplasia (BPH) is a common disease affecting male urinary system function and quality of life, with its incidence increasing due to population ageing and unhealthy lifestyles. Modern medicine mainly adopts symptomatic treatments such as 5-alpha reductase inhibitors and alpha1 adrenergic receptor blockers. However, due to the complex pathogenesis of BPH, these drugs can only partially alleviate symptoms and have shortcomings such as high treatment costs and significant side effects. BPH is similar to the descriptions of “Jīng Lóng” and “Lóng Bì” in traditional Chinese medicine (TCM), and its onset is closely related to liver and kidney dysfunction. Kidney insufficiency and blood stasis are common clinical syndromes of BPH. Compared with modern medicine, treatment based on syndrome differentiation of TCM can achieve good results in treating this subtype of BPH. Therefore, guided by the holistic view of TCM, adopting a holistic and systematic research approach to explore therapeutic targets and potential therapeutic components for BPH with a specific syndrome can provide new ideas for the clinical treatment of BPH. This study integrated clinical metabolomics and network pharmacology to identify therapeutic targets for kidney insufficiency and blood stasis-type BPH. Serum analysis of BPH patients and healthy controls for testosterone, estradiol, SRD5α2, NF-κB p65, and TGF-β levels, alongside metabolomics and network pharmacology, revealed hormonal imbalance, increased inflammatory/fibrotic markers, and 58 differential metabolites in BPH. Pathway enrichment analysis identified 6 key metabolic pathways, while network pharmacology constructed four compound-reaction-enzyme-gene networks and pinpointed 178 potential targets, including 23 core targets. Reverse screening against the Yaozh Database-Natural Product AI Engine Platform matched 11 druggable targets with 49 interacting components, and target-component fitting analysis confirmed the reliability of 8 core targets. This combined approach validated the findings of hormonal imbalance and significant metabolic pathway changes and provided valuable insights for BPH treatment and drug development. |
| format | Article |
| id | doaj-art-dff119ee45e3450ea3f7a01b1781af51 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-dff119ee45e3450ea3f7a01b1781af512025-08-20T02:10:24ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.15847661584766Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screeningXiangpeng Kong0Xiangpeng Kong1Haiqin Ren2Ke Pei3Yajun Yao4Zhigang Liang5Yunfeng Xue6Shuang Liang7Tongtong Li8Jing Zhang9Yuxia Guo10Miaorong Pei11Huifeng Li12Institute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaShanxi Province Doctor Innovation Station (Shanxi Zhendong WuheTang Pharmaceutical Co., Ltd. Station), Changzhi, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaDepartment of Chinese Medicine, Shanxi Pharmaceutical Vocational College, Taiyuan, ChinaDepartment of Andrology, The Affiliated Hospital of Shanxi University of Chinese Medicine, Taiyuan, ChinaDepartment of Andrology, The Affiliated Hospital of Shanxi University of Chinese Medicine, Taiyuan, ChinaThe Third Clinical College, Shanxi University of Chinese Medicine, Jinzhong, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaInstitute of Pharmaceutical & Food Engineering, Chinese Medicine Master Studio of Wang Shimin, Shanxi University of Chinese Medicine, Jinzhong, ChinaBenign prostatic hyperplasia (BPH) is a common disease affecting male urinary system function and quality of life, with its incidence increasing due to population ageing and unhealthy lifestyles. Modern medicine mainly adopts symptomatic treatments such as 5-alpha reductase inhibitors and alpha1 adrenergic receptor blockers. However, due to the complex pathogenesis of BPH, these drugs can only partially alleviate symptoms and have shortcomings such as high treatment costs and significant side effects. BPH is similar to the descriptions of “Jīng Lóng” and “Lóng Bì” in traditional Chinese medicine (TCM), and its onset is closely related to liver and kidney dysfunction. Kidney insufficiency and blood stasis are common clinical syndromes of BPH. Compared with modern medicine, treatment based on syndrome differentiation of TCM can achieve good results in treating this subtype of BPH. Therefore, guided by the holistic view of TCM, adopting a holistic and systematic research approach to explore therapeutic targets and potential therapeutic components for BPH with a specific syndrome can provide new ideas for the clinical treatment of BPH. This study integrated clinical metabolomics and network pharmacology to identify therapeutic targets for kidney insufficiency and blood stasis-type BPH. Serum analysis of BPH patients and healthy controls for testosterone, estradiol, SRD5α2, NF-κB p65, and TGF-β levels, alongside metabolomics and network pharmacology, revealed hormonal imbalance, increased inflammatory/fibrotic markers, and 58 differential metabolites in BPH. Pathway enrichment analysis identified 6 key metabolic pathways, while network pharmacology constructed four compound-reaction-enzyme-gene networks and pinpointed 178 potential targets, including 23 core targets. Reverse screening against the Yaozh Database-Natural Product AI Engine Platform matched 11 druggable targets with 49 interacting components, and target-component fitting analysis confirmed the reliability of 8 core targets. This combined approach validated the findings of hormonal imbalance and significant metabolic pathway changes and provided valuable insights for BPH treatment and drug development.https://www.frontiersin.org/articles/10.3389/fphar.2025.1584766/fullbenign prostatic hyperplasia (BPH)kidney insufficiency and blood stasismetabolomicsnetwork pharmacologyintegrationtarget |
| spellingShingle | Xiangpeng Kong Xiangpeng Kong Haiqin Ren Ke Pei Yajun Yao Zhigang Liang Yunfeng Xue Shuang Liang Tongtong Li Jing Zhang Yuxia Guo Miaorong Pei Huifeng Li Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening Frontiers in Pharmacology benign prostatic hyperplasia (BPH) kidney insufficiency and blood stasis metabolomics network pharmacology integration target |
| title | Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening |
| title_full | Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening |
| title_fullStr | Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening |
| title_full_unstemmed | Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening |
| title_short | Unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis-type BPH: bridging metabolomics, network pharmacology and reverse screening |
| title_sort | unveiling therapeutic targets and preventive components for kidney insufficiency and blood stasis type bph bridging metabolomics network pharmacology and reverse screening |
| topic | benign prostatic hyperplasia (BPH) kidney insufficiency and blood stasis metabolomics network pharmacology integration target |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1584766/full |
| work_keys_str_mv | AT xiangpengkong unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT xiangpengkong unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT haiqinren unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT kepei unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT yajunyao unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT zhigangliang unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT yunfengxue unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT shuangliang unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT tongtongli unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT jingzhang unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT yuxiaguo unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT miaorongpei unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening AT huifengli unveilingtherapeutictargetsandpreventivecomponentsforkidneyinsufficiencyandbloodstasistypebphbridgingmetabolomicsnetworkpharmacologyandreversescreening |